DFTX

Definium Therapeutics, Inc.

September 14, 2026 · pre-market

Rarity

2.19

Peak move

+19.15%

Float cap

$3.7B

Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders in adults. Its lead candidates include DT120 ODT, a proprietary form of lysergide D-tartrate being developed for generalized anxiety disorder and major depressive disorder, and DT402, an R(-)-MDMA candidate for autism spectrum disorder.

• analyst_ratingSep 14 · 08:06 ET

  Needham & Company LLC reiterated a Buy rating on Definium Therapeutics with a $66.00 price target, implying 69.71% upside from the prior close.

  Webmarketbeat.com
• reg_fd_disclosureSep 14

  Definium Therapeutics announced inducement grants of options to purchase an aggregate 56,650 common shares to three newly hired non-executive employees, effective September 14, 2026, with Compensation Committee approval on September 11, 2026 under Nasdaq Rule 5635(c)(4), an exercise price equal to the closing price that date and four-year vesting.

  Webbusinesswire.comWebadvfn.com
• clinical_readoutSep 13 · 21:23 ET

  Definium Therapeutics reported positive topline results from Panorama, its second Phase 3 trial of DT120 (LSD-based orally disintegrating tablet) in generalized anxiety disorder, enrolling 245 adults across 32 centers, with the 100 µg dose reducing HAM-A total score by 9.8 points at Week 12 versus 4.7 for placebo (effect size d=0.64) and no serious adverse events.

  Webfinance.yahoo.comWebbusinesswirenews.comWebbusinesswirenews.comSEC8-K 0001104659-26-107275Webgurufocus.com